What's Going On With ASLAN Pharmaceuticals Stock Today?

ASLAN Pharmaceuticals Ltd ASLN released topline data from its TREK-AD Phase 2b dose-ranging study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis (AD).

Eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo with statistical significance in three dosing arms: 600mg dosed once every four weeks (600mg Q4W), which was numerically the best-performing arm, 400mg dosed once every two weeks (400mg Q2W) and 300mg dosed once every two weeks (300mg Q2W).

600mg eblasakimab dosed once every four weeks in the TREK-AD study met the primary endpoint with statistical significance, with 62.7% of patients achieving EASI-75, 34.1% reaching EASI-90 and 31.2% achieving vIGA-AD of 0 or 1.

Regimens dosing once every two weeks also met the primary endpoint with statistical significance, as well as meeting key secondary endpoints.

The company said eblasakimab 400mg Q4W dosing arm did not meet the primary or secondary endpoints with statistical significance.

Further data from the Phase 2b study is expected in Q4 2023. ASLAN plans to meet with the FDA for an end-of-Phase 2 meeting and expects to initiate a Phase 3 clinical development program for eblasakimab in 2024. 

The company is also conducting the TREK-DX study of eblasakimab in dupilumab-experienced patients and expects to announce topline data from that study in 1Q 2024.

ASLN shares were down by almost 14% in the premarket at one point. It has recovered from the losses since.

Price Action: ASLN shares are down 0.26% at $3.80 during the premarket session on the last check Thursday.